SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-078049
Filing Date
2023-09-20
Accepted
2023-09-20 16:47:21
Documents
16
Period of Report
2023-09-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea185487-8k_relmada.htm   iXBRL 8-K 36742
2 PRESS RELEASE ISSUED ON SEPTEMBER 20, 2023 ea185487ex99-1_relmada.htm EX-99.1 32392
3 GRAPHIC ex99-1_001.jpg GRAPHIC 12069
4 GRAPHIC ex99-1_002.jpg GRAPHIC 16042
5 GRAPHIC ex99-1_003.jpg GRAPHIC 9636
  Complete submission text file 0001213900-23-078049.txt   301851

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE rlmd-20230920.xsd EX-101.SCH 3012
7 XBRL LABEL FILE rlmd-20230920_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE rlmd-20230920_pre.xml EX-101.PRE 22357
10 EXTRACTED XBRL INSTANCE DOCUMENT ea185487-8k_relmada_htm.xml XML 3326
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 231266970
SIC: 2834 Pharmaceutical Preparations